171 related articles for article (PubMed ID: 37302574)
1. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
[TBL] [Abstract][Full Text] [Related]
2. Role of autoantibodies in the clinical management of primary biliary cholangitis.
Rigopoulou EI; Bogdanos DP
World J Gastroenterol; 2023 Mar; 29(12):1795-1810. PubMed ID: 37032725
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
[TBL] [Abstract][Full Text] [Related]
4. [Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis].
Romero Gómez M; Wichmann I; Otero Fernández MA; Suárez García E; Grande L; Núñez J; Nevado Santos M; Castro Fernández M
Gastroenterol Hepatol; 1999 Jan; 22(1):11-3. PubMed ID: 10089705
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
[TBL] [Abstract][Full Text] [Related]
7. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
[TBL] [Abstract][Full Text] [Related]
8. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report.
Zhao DT; Liu YM; Han Y; Zhang HP; Zhao Y; Yan HP
Medicine (Baltimore); 2020 Jan; 99(3):e18856. PubMed ID: 32011506
[TBL] [Abstract][Full Text] [Related]
9. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.
Luettig B; Boeker KH; Schoessler W; Will H; Loges S; Schmidt E; Worman HJ; Gershwin ME; Manns MP
J Hepatol; 1998 May; 28(5):824-8. PubMed ID: 9625318
[TBL] [Abstract][Full Text] [Related]
10. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune Markers in Primary Biliary Cholangitis.
Shah SK; Bowlus CL
Clin Liver Dis; 2024 Feb; 28(1):93-101. PubMed ID: 37945165
[TBL] [Abstract][Full Text] [Related]
12. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
13. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
[TBL] [Abstract][Full Text] [Related]
14. [How to understand the clinical significance of autoantibodies in primary biliary cholangitis].
Yan HP; Zhang HP; Chen XX
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):810-815. PubMed ID: 29325273
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.
Itoh S; Ichida T; Yoshida T; Hayakawa A; Uchida M; Tashiro-Itoh T; Matsuda Y; Ishihara K; Asakura H
J Gastroenterol Hepatol; 1998 Mar; 13(3):257-65. PubMed ID: 9570238
[TBL] [Abstract][Full Text] [Related]
16. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
[No Abstract] [Full Text] [Related]
17. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
Nakamura M; Shimizu-Yoshida Y; Takii Y; Komori A; Yokoyama T; Ueki T; Daikoku M; Yano K; Matsumoto T; Migita K; Yatsuhashi H; Ito M; Masaki N; Adachi H; Watanabe Y; Nakamura Y; Saoshiro T; Sodeyama T; Koga M; Shimoda S; Ishibashi H
J Hepatol; 2005 Mar; 42(3):386-92. PubMed ID: 15710222
[TBL] [Abstract][Full Text] [Related]
18. [Primary biliary cholangitis].
Soret PA; Chazouillères O; Corpechot C
Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis.
Nakamura M; Takii Y; Ito M; Komori A; Yokoyama T; Shimizu-Yoshida Y; Koyabu M; Matsuyama M; Mori T; Kamihira T; Daikoku M; Migita K; Yatsuhashi H; Nozaki N; Shimoda S; Ishibashi H
J Autoimmun; 2006 Mar; 26(2):138-45. PubMed ID: 16337775
[TBL] [Abstract][Full Text] [Related]
20. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
